Bipolar

Olympus Announces Full Market Availability of Redesigned Energy Platform

Retrieved on: 
Wednesday, January 24, 2024
LCD, HF, Olympus Corporation, Hospital, General surgery, Elective surgery, Urology, Injury, Turís, Society, Operating, Gynaecology, STS, Plasma, Bipolar, Movement, System

CENTER VALLEY, Pa., Jan. 24, 2024 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today full market availability of its new ESG-410™ Surgical Energy Platform for conventional monopolar and bipolar, advanced energy applications now including ultrasonic dissection and hybrid energy.

Key Points: 
  • The ESG-410™ Surgical Energy Platform, the Heart of Every Procedure, Positions Olympus as a Comprehensive Energy Solution Provider
    CENTER VALLEY, Pa., Jan. 24, 2024 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today full market availability of its new ESG-410™ Surgical Energy Platform for conventional monopolar and bipolar, advanced energy applications now including ultrasonic dissection and hybrid energy.
  • The ESG-410 Surgical Energy Platform delivers a comprehensive energy solution with applications across numerous specialties such as general surgery, thoracic surgery, urology, and gynecology.
  • The ESG-410 generator is part of the Olympus energy portfolio that offers hospitals an all-in-one energy solution for any operating room and powers the full range of Olympus Energy systems: monopolar, bipolar (HiQ™, HICURA™, PK™ and Everest™ devices), ultrasonic (SONICBEAT™ devices), hybrid energy (THUNDERBEAT™ devices) and advanced bipolar (POWERSEAL™ devices).
  • For more information, visit the Olympus booth #1831 at STS or for more information about the Olympus energy portfolio visit the POWERSEAL , THUNDERBEAT and ESG-410 product pages.

Psyclarity Health Massachusetts Expands its Mental Health and Addiction Treatment Services

Retrieved on: 
Friday, January 19, 2024
Empowerment, Woman, Family, Patient, Depression, Trauma, PTSD, Secure, Health, Eating, LGBTQ, Inclusive, Rehabilitation, Workplace, Anxiety, Environment, Family therapy, Mentorship, Bipolar, Safety, Dialectical behavior therapy, Fear, Substance abuse, Loneliness, Nursing

SAUGUS, Mass., Jan. 18, 2024 /PRNewswire/ -- Psyclarity Health has always been a go-to resource for those seeking effective addiction and mental health treatment for men. Now, these resources have been expanded with treatment modalities and staff tailored specifically for women.

Key Points: 
  • Psyclarity Health, a leading behavioral health service provider, has broadened its services to include comprehensive, compassionate, and gender-specific care for women.
  • SAUGUS, Mass., Jan. 18, 2024 /PRNewswire/ -- Psyclarity Health has always been a go-to resource for those seeking effective addiction and mental health treatment for men.
  • Psyclarity Health aims to fulfill these needs by offering access to state-of-the-art addiction treatment services tailored to any patient, regardless of their gender needs.
  • Inclusivity: Psyclarity Health addiction treatment centers can accept and accommodate members of the LGBTQ community.

NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event

Retrieved on: 
Monday, December 11, 2023
Therapy, Dark Enlightenment, Urine, Pain, GMP, HOPE, Beacon Grand Hotel, Comment, IND, DCS, Patient, Alvogen, FDA, DSM-IV codes, Cyclothymia, Conference, NIH, Low back pain, HEAL, Powell Street, Chronic pain, Ketamine, Bipolar, Pharmaceutical industry

RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Key Points: 
  • RADNOR, Pa., Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.
  • NRx currently has four (4) near-term shots on goal with meaningful commercial and/or monetization opportunities:
    NRX-100 – Intravenous Ketamine.
  • NRx will be hosting 1x1 meetings at the Beacon Grand Hotel (450 Powell Street, a block away from the JP Morgan Conference at Union Square).
  • To schedule a meeting, please register at LifeSci Partners Corporate Access Event 2024 and request a meeting with management.

Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Wellcome Trust, Trust, Ketamine, MTD, Trial of the century, DSM-IV codes, Esketamine, EudraCT, Drug, Conference, SAD, Pharmacodynamics, Psychology, MHRA, Index, Marketing, Bipolar, Spectrum, Depression, Safety, International Society, Patient, Pharmaceutical industry, Vaccine

At several KET-IR dose levels, ketamine and ketamine metabolite blood concentrations were similar to those reported for intranasal esketamine, which is used to treat patients with treatment-resistant depression, and with intravenous ketamine.

Key Points: 
  • At several KET-IR dose levels, ketamine and ketamine metabolite blood concentrations were similar to those reported for intranasal esketamine, which is used to treat patients with treatment-resistant depression, and with intravenous ketamine.
  • Pharmacodynamic effects known to be associated with ketamine therapy, such as dissociation and mild sedation, were apparent at several doses.
  • “We are encouraged by the results of our phase 1 study of KET-IR.”, added Graeme Duncan, Head of Clinical Development at Neurocentrx.
  • Blood levels of ketamine and ketamine metabolites were similar to levels associated with therapeutic ketamine administration at several dose levels (Perez-Ruixo et al.

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Retrieved on: 
Wednesday, October 4, 2023
Patent, The Orange Book, Dexmedetomidine, Aes, Part, II, Agitation, Orange Book, Incidence, Dementia, Shanda, PEC, Live, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, Bipolar, Artificial intelligence, Security (finance), FDA, Therapy, Noa Pothoven, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, DSM-IV codes, Pharmaceutical industry, HAVEN, Schizophrenia

NEW HAVEN, Conn., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience, today provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film. These developments include meetings scheduled with the U.S. Food and Drug Administration (FDA) to discuss the TRANQUILITY and SERENITY III clinical programs and the receipt of two Notices of Allowance (NOAs) from the U.S. Patent and Trademark Office to extend method of use patent protection for sublingual dexmedetomidine.

Key Points: 
  • “The meetings with the FDA are critical components of our business strategy.
  • The briefing book submitted to FDA for the meeting includes results from 11 double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating the safety and efficacy of BXCL501.
  • The Company now has four U.S. patents claiming formulations of dexmedetomidine with exclusivity until 2039 currently listed in the Orange Book.
  • These patents further broaden the scope of intellectual property estate for IGALMI™ and for future potential indications.

Divine Well-Being: A new study examines the mental health advantages of being religious or spiritual, as well as the potential drawbacks

Retrieved on: 
Wednesday, September 20, 2023
LEARN, Depression, Religion, Face, Spirituality, Disability, AND, Emotion, Believer, Hardship, Thought, Mood disorder, Love, Happiness, HR, Knowledge, Hand, Mental health, Bipolar, Nursing, Management

MONTREAL, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Religion and controversy frequently go hand in hand. However, when focusing strictly on the benefits of faith in a divine being—or, in the case of spiritualists, something greater than ourselves—studies have uncovered a number of advantages. Adding to the body of knowledge is a recent study by the psychometricians at Psychtests.com, which reveals that religiosity and spirituality encourage people to grow, improve, and stay strong in the face of hardship, but they can also, in some cases, result in distorted thinking.

Key Points: 
  • However, when focusing strictly on the benefits of faith in a divine being—or, in the case of spiritualists, something greater than ourselves—studies have uncovered a number of advantages.
  • Faith alone will not bring you happiness or success; you always need to take steps aligned with your goals or vision.
  • Here's what their investigation revealed:
    90% believe that they deserve love, respect, and happiness (compared to 77% of Non-believers).
  • This type of defense mechanism, known as "Reaction Formation," is a method of redirecting a negative impulse into something positive.

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

Retrieved on: 
Monday, August 14, 2023
Workforce, Partnership, ALF, SG, Schizophrenia, New Drug Application, Clinical trial, Part, Element, R, Sale, II, Breakthrough therapy, Selective serotonin reuptake inhibitor, Incidence, Nursing, Dementia, PEC, Hospital, Shanda, Patient, Administration, Protocol amending the Single Convention on Narcotic Drugs, Lunatic, Breakthrough, Toxicology, Webcast, Artificial intelligence, MAD, Research and development, Bipolar, AI, Research, FDA, Therapy, POC, Qatar Investment Authority, Agitation, Pharmacology, Safety, DSM-IV codes, Medical device, Fine chemical, Pharmaceutical industry, Medical imaging, Audit

ET today

Key Points: 
  • ET today
    NEW HAVEN, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second quarter ended June 30, 2023, and a strategic reprioritization to strengthen its focus and significantly reduce operating expenses.
  • Continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing or strategic partnership, M&A, or sale.
  • Net Loss: BioXcel Therapeutics had a net loss of $53.5 million for the second quarter of 2023, compared to a net loss of $37.7 million for the same period in 2022.
  • ET to discuss its second quarter 2023 financial results and provide an update on recent operational highlights.

Photonis Expands Market-Leading Mass Spectrometry Detection Technology

Retrieved on: 
Tuesday, May 23, 2023
Microchannel plate detector, American Society for Mass Spectrometry, Partnership, ASMS, Mass spectrometry, A300, George R. Brown Convention Center, Quality of life, AC, MS, Research and development, Development, Investment, Research, Microchannel, Society, Conference, Bipolar, Medical imaging

Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.

Key Points: 
  • Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.
  • At this occasion, Photonis, the leaders in Time-of-Flight (TOF) detection technologies, will showcase their latest advancements in TOF detection with additions to their existing detector platforms - the APTOF and BPTOF Series.
  • Ulrich Laupper, President and General Manager of Photonis' Ultimate Detection Business Unit: "We are excited to introduce the next generation of Time-of-Flight detection technology at this year's ASMS Conference.
  • The APTOF A300 and BPTOF B380 provide mass spectrometry instrument manufacturers an unmatched cost-of-ownership value proposition.

Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management

Retrieved on: 
Thursday, June 22, 2023
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Jennifer Fox, Bear Stearns, Migraine, Depression, Biochemistry, Diabetes, Doctor of Philosophy, Marketing, Schizophrenia, Elizabeth Glaser Pediatric AIDS Foundation, Texas A&M University, Biogen, CMC, Atrial fibrillation, ODT, Business, Atopic dermatitis, MBA, MIT, Merck & Co., Bristol Myers Squibb, Deutsche Bank, AstraZeneca, Prudential Securities, Chronic obstructive pulmonary disease, Chemistry, Organization, Neuroscience, Bank of America, CDMO, Bowdoin College, Citigroup, Engineering, Boehringer Ingelheim, CFO, Merck, United States Department of the Air Force, Bank, Stanford Graduate School of Business, Therapy, Nitrome, Bipolar, Pfizer, Takeda Pharmaceutical Company, Pharmaceutical industry, Management, Manhattan College, Apsis

Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.

Key Points: 
  • Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.
  • “We are thrilled to further strengthen the Apogee team with the appointments of both Jennifer and BJ to our board of directors and Becky to our senior management team, and to leverage their respective expertise in the industry,” said Michael Henderson, M.D., chief executive officer of Apogee.
  • Ms. Fox currently serves on the board of directors and as chair of the audit committee of ProKidney Corp. and on the board of directors of Life Science Cares.
  • Dr. Dabora has served in executive roles leading the technical operations function for several companies, including Invivyd, Aspyrian Therapeutics, SwanBio Therapeutics and others.

LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study

Retrieved on: 
Tuesday, June 13, 2023
Research, Mental Health, Medical Devices, Hospitals, FDA, Clinical Trials, Health Technology, Cardiology, Health, Science, VNS, Interim, CMS, Depression, PLC, Centers for Medicare & Medicaid Services, LIVN, Safety, Quality of life, LivaNova, Adjunct (grammar), Washington University in St. Louis, Trial of the century, Medicare, Hospital, Patient, Grammatical mood, Effectiveness, Principal, DSM-IV codes, Bipolar, Pharmaceutical industry

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study , “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy™ System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.” The RECOVER protocol allows for a minimum of 150 and a maximum of 500 bipolar depression patients to be randomized into the study.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study , “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy™ System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.” The RECOVER protocol allows for a minimum of 150 and a maximum of 500 bipolar depression patients to be randomized into the study.
  • Now, having randomized the 150th bipolar patient, a series of interim analyses will be conducted by an independent Statistical Analysis Committee to assess if predictive probability of success has been reached for the bipolar cohort of the study.
  • “The RECOVER study is progressing well having completed enrollment for the unipolar patient cohort at 500 and now achieving a major milestone with 150 bipolar patients randomized in this groundbreaking depression study,” said Dr. Charles R. Conway, Director of the Washington University Resistant Mood Disorders Center, who serves as Principal Investigator for RECOVER.
  • For more information on the RECOVER clinical study, please visit www.RecoverVNS.com .